Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.91 and traded as high as $7.80. Achieve Life Sciences shares last traded at $7.80, with a volume of 119,644 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Maxim Group reiterated a “buy” rating and issued a $8.00 target price on shares of Achieve Life Sciences in a research report on Friday, March 17th. Oppenheimer restated an “outperform” rating and set a $17.00 price target on shares of Achieve Life Sciences in a research note on Friday, March 17th.
Achieve Life Sciences Trading Up 7.6 %
The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $5.53 and its two-hundred day simple moving average is $3.91. The stock has a market capitalization of $139.85 million, a P/E ratio of -1.92 and a beta of 1.51.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last announced its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same quarter in the prior year, the company earned ($0.76) EPS. As a group, analysts forecast that Achieve Life Sciences, Inc. will post -1.94 earnings per share for the current year.
Institutional Investors Weigh In On Achieve Life Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LP acquired a new stake in shares of Achieve Life Sciences during the 4th quarter worth approximately $32,000. Morgan Stanley increased its holdings in Achieve Life Sciences by 437.4% during the fourth quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 11,026 shares during the last quarter. Prelude Capital Management LLC acquired a new position in Achieve Life Sciences during the second quarter worth $49,000. Jane Street Group LLC bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth about $53,000. Finally, Raymond James & Associates increased its position in Achieve Life Sciences by 34.6% during the third quarter. Raymond James & Associates now owns 17,431 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 4,482 shares during the period. Institutional investors and hedge funds own 21.11% of the company’s stock.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
See Also
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.